Parkinson’s Treatment Market Set for Growth Through 2036

The sector's momentum follows the recent FDA approval of AbbVie’s JUVMO, the first selective D1/D5 receptor agonist for the condition. This development marks a shift in the landscape, where pharmaceutical investment is increasingly focused on both symptomatic management and disease-modifying approaches. Companies such as BlueRock Therapeutics, Bayer, Cerevance, and Annovis Bio are currently advancing a pipeline of novel therapies, including stem cell-derived treatments and targeted drug-delivery systems, to address the needs of an estimated 3 million diagnosed patients across major global markets.

Treatment strategies are moving toward highly personalized care, incorporating digital monitoring and biomarker research to better manage disease progression. While pharmacological standards like carbidopa/levodopa remain the cornerstone of therapy, the integration of advanced options—such as continuous subcutaneous infusion and device-aided interventions—is providing new alternatives for patients with advanced symptoms. As these emerging therapies transition from clinical trials to commercial availability, the market is expected to see a broader adoption of premium treatments, reshaping the standard of care through 2036.